Clinical trials: Venous Thromboembolic Event
Venous Thromboembolism (VTE), Deep Vein Thrombosis (DVT)
Cancer Venous Thromboembolism (VTE)
The primary objective is to demonstrate the non-inferiority of edoxaban (preceded by a short course of LMWH) compared with dalteparin for the prevention of the combined outcome of recurrent venous thromboembolism (VTE) or major…
- Conditions
- Venous Thromboembolism (VTE), Deep Vein Thrombosis (DVT), Pulmonary Embolism (PE), Cancer
- Trial name
- NCT02073682
- Testing
- Edoxaban, Dalteparin, Low molecular weight heparin
- Where
- 9 sites in United States, Belgium and 4 more
- Volunteers
- 1,046 people
- Sponsor
- Daiichi Sankyo
Venous Thromboembolism
An Oral, Direct Factor Xa Inhibitor, BAY59-7939, for Prophylaxis Against Venous Thromboembolism After Total Knee Replacement: a Dose-Ranging Study
The study drug, BAY59-7939, is a new drug currently being tested in the prevention of VTE. It directly inhibits factor Xa, a blood component in the pathway which leads to coagulation (clotting of blood cells).
- Trial name
- NCT00402467
- Testing
- Rivaroxaban (BAY59-7939), Rivaroxaban, (BAY59-7939), Enoxaparine
- Where
- 36 sites in United States, Canada
- Volunteers
- 613 people
- Sponsor
- Bayer
Pulmonary Embolism, Venous Thromboembolic Disease
Prospective, Multi-center, Single-arm Study to Assess the Safety of Retrieval of the Recovery G2 Filter.
This study was designed to assess the safety of retrieval of the Bard Recovery® G2® Filter System. The G2 filter is an FDA-cleared device for inferior vena caval interruption in patients with pulmonary thromboembolism.
- Trial name
- EVEREST (NCT00556426)
- Testing
- Bard Recovery G2 Filter System
- Volunteers
- 100 people
- Sponsor
- C. R. Bard
Venous Thromboembolism
Evaluation of AVE5026 as Compared to Placebo for the Extended Prophylaxis of Venous Thromboembolism in Patients Having Undergone Hip Fracture Surgery
The primary objective is to evaluate the efficacy of once daily (QD) subcutaneous (SC) injections of Semuloparin sodium (AVE5026) versus placebo for 3 additional weeks following an initial 7 to 10-day venous thromboprophylaxis…
- Trial name
- SAVE-HIP3 (NCT00709904)
- Testing
- Open-label Semuloparin sodium, Semuloparin sodium
- Where
- 16 sites in United States, Belarus and 14 more
- Volunteers
- 469 people
- Sponsor
- Sanofi
Contraception, Female Contraception
Relative Risks for Non-fatal Venous Thromboembolism, Ischemic Stroke and Myocardial Infarction in Users of ORTHO EVRA(Norelgestromin and Ethinyl Estradiol Contraceptive Patch) Compared to Levonorgestrel-containing Oral Contraceptives.
This study uses the PharMetrics and MarketScan US health care insurance claims database to estimate relative risks for non-fatal venous thromboembolism (including cerebral venous sinus thrombosis), ischemic stroke, and acute…
- Conditions
- Contraception, Female Contraception, Fertility Control
- Trial name
- NCT00511784
- Volunteers
- 440 people, healthy volunteers welcome
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Pulmonary Embolism
Crux Biomedical Evaluation of the Crux Inferior Vena Cava Filter 4
The purpose of this study is to determine if the Crux Vena Cava Filter System is safe and effective in preventing pulmonary embolism.
- Trial name
- RETRIEVE 4 (NCT01120535)
- Testing
- Inferior Vena Cava Filter
- Where
- 3 sites in Australia, New Zealand
- Volunteers
- 20 people
- Sponsor
- Crux Biomedical
Venous Thromboembolism
EINSTEIN Junior Phase II: Oral Rivaroxaban in Young Children With Venous Thrombosis
The purpose of this study is to find out whether rivaroxaban is safe to use in children and how long it stays in the body. Safety will be assessed by looking at the incidence and types of bleeding events.
- Trial name
- EINSTEINJr (NCT02309411)
- Testing
- Rivaroxaban (Xarelto, BAY59-7939)
- Where
- 29 sites in United States, Australia and 13 more
- Volunteers
- 46 people
- Sponsor
- Bayer
Venous Thromboembolism
Pharmacokinetic (PK) Assessment of BIBR 1048 in Patients After Primary Elective Total Hip Replacement Surgery
To determine the PK profile of a single dose 150 mg BIBR 1048, oral capsule, administered 1-3 hours post surgery in hip replacement patients.
- Trial name
- NCT02170935
- Testing
- BIBR 1048 capsule
- Volunteers
- 62 people
- Sponsor
- Boehringer Ingelheim
Venous Thrombosis
Evaluation of PD 0348292 for Preventing Blood Clots in the Lungs or Deep Leg Veins of Patients After Knee Surgery
To study the safety and effectiveness of several doses of PD 0348292 compared to enoxaparin in preventing blood clots in the lungs or deep leg veins of patients after knee surgery
- Trial name
- NCT00306254
- Testing
- PD 0348292, Enoxaparin
- Where
- 134 sites in United States, Australia and 14 more
- Volunteers
- 1,225 people
- Sponsor
- Pfizer
Venous Thrombosis
Venous Thromboembolism Taskforce Audit Program
To determine the effect of an interventional campaign run by a dedicated "VTE Nurse Educator" over a 6-month period and the effect on prophylaxis rates.
- Trial name
- NCT00535171
- Where
- Australia
- Volunteers
- 8,764 people
- Sponsor
- Sanofi
Contraception, Female Contraception
Postmarketing Study of ORTHO EVRA (Norelgestromin and Ethinyl Estradiol Contraceptive Patch) in Relation to Venous Thromboembolism (Blood Clots), Stroke and Heart Attacks
The purpose of the study is to assess the occurrence of venous thromboembolism (blood clots), stroke, and heart attack in current users of ORTHO EVRA compared to current users of norgestimate-containing oral contraceptives with…
- Trial name
- NCT00331071
- Testing
- Monophasic or triphasic Oral contraceptive tablet, Ortho Evra transdermal patch containing 6 mg NGMN/0.75 mg EE
- Volunteers
- 334 people, healthy volunteers welcome
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Cancer
Evaluation of Dalteparin for Long-term (One Year) Treatment of Blood Clots in Subjects With Cancer
The purpose of this study is to determine the long term tolerability and safety of dalteparin in subjects with cancer.
- Trial name
- NCT00942968
- Testing
- dalteparin
- Where
- 42 sites in United States, Austria and 3 more
- Volunteers
- 338 people
- Sponsor
- Pfizer
Venous Thromboses, Venous Thromboembolism
The Risk of Venous Thromboembolism in Systemic Inflammatory Disorders: a United Kingdom (UK) Matched Cohort Study
Blood clots occurring in the legs and in the lungs are relatively common; they occur in around 3 in a 1000 people per year. They can cause disability and are also potentially life threatening.
- Conditions
- Venous Thromboses, Venous Thromboembolism, Deep Vein Thrombosis, Pulmonary Embolism
- Trial name
- NCT03835780
- Testing
- No intervention
- Where
- United Kingdom
- Volunteers
- 266,890 people, healthy volunteers welcome
- Sponsor
- Momentum Data
Venous Thromboembolism
Effect of Clarithromycin on the Pharmacokinetics of Apixaban in Healthy Participants
This study is to evaluate the effects of multiple-dose clarithromycin on the single-dose pharmacokinetics (PK) of apixaban with parameters like Cmax, AUC(INF), and AUC(0-T).
- Trial name
- NCT02912234
- Testing
- Apixaban, Clarithromycin
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Bristol-Myers Squibb
Thromboembolism, Arthroplasty, Replacement, Hip
Study to Evaluate the Safety and Efficacy of Pradaxar for the Prevention of Venous Thromboembolism in the Mexican Population Undergoing Elective Total Hip or Knee Replacement Surgery
Open, prospective, uncontrolled, observational cohort study.
- Trial name
- NCT00967447
- Where
- 28 sites in Mexico
- Volunteers
- 2 people
- Sponsor
- Boehringer Ingelheim
Venous Thromboembolism, Pulmonary Embolism
Exclusion of Venous Thrombo-Embolism With a New Clinical Decision Support
The goal of this non interventional study is to demonstrate the diagnostic performances on fresh plasmas in comparison with the performances on frozen plasmas in any patients with VTE suspicion, whatever the pre-test probability.
- Conditions
- Venous Thromboembolism, Pulmonary Embolism, Deep Vein Thrombosis
- Trial name
- EXTEND (NCT06480994)
- Testing
- Routine Assays on fresh plasma, New Clinical Decision Support on fresh plasma, New Clinical Decision Support on frozen plasma
- Where
- 4 sites in France
- Volunteers
- 1,836 people
- Sponsor
- Diagnostica Stago R&D
Venous Thromboembolism
Efficacy of Sodium Heparin for Prophylaxis of Venous Thromboembolism in Surgical Patients
The aim of this study is to verify, through clinical examination and doppler, the non-inferiority of the drug test (heparin sodium 5.000UI/0.25 mL - HIPOLABOR) in relation to the drug compared (heparin sodium 5.000USP/mL - APP)…
- Trial name
- NCT00934167
- Testing
- heparin sodium - Hipolabor, Heparin sodium - APP
- Where
- Brazil
- Volunteers
- 140 people, healthy volunteers welcome
- Sponsor
- Azidus Brasil
Multiple Myeloma, Myelodysplastic Syndromes
A Study of Special Use Results Surveillance of Revlimid 5mg Capsules
To understand the safety and efficacy of Revlimid® 5 mg Capsules (hereinafter referred to as Revlimid) in all patients who are treated with it under the actual condition of use pursuant to the conditions of approval. 1.
- Trial name
- NCT02921802
- Where
- Japan
- Volunteers
- 4,626 people
- Sponsor
- Celgene
Thrombosis, Venous
A Study to Evaluate the Efficacy and Safety of Fondaparinux for the Prevention of Venous Blood Clots in Patients With a Plaster Cast or Other Type of Immobilization for a Below-knee Injury Not Needing Surgery
The purpose of this study is to evaluate the efficacy and safety of fondaparinux in comparison with a heparin (nadroparin) in preventing deep vein thrombosis (blood clots in the leg veins), whether symptomatic or detected by…
- Trial name
- FONDACAST (NCT00843492)
- Testing
- Fondaparinux sodium, Nadroparin
- Where
- 122 sites in France, Germany and 4 more
- Volunteers
- 1,351 people
- Sponsor
- GlaxoSmithKline
Venous Thromboembolism (VTE)
Treatment and Secondary Prevention of Venous Thromboembolism (VTE) in Adult Participants With Solid and Hematologic Cancers
This study is researching an experimental drug called REGN7508 (called "study drug") and will consist of 2 parts: Part 1 and Part 2.
- Trial name
- ROXI-CAT-II (NCT07493304)
- Testing
- REGN7508, Apixaban
- Where
- 14 sites in United States, Bulgaria and 3 more
- Volunteers
- 1,600 people
- Sponsor
- Regeneron Pharmaceuticals